Drug Addiction Pipeline Review H2 2015

1. Drug Addiction - Pipeline Review, H2 2015 By RnRMarketResearch.com Publisher Name : Global Markets Direct Date: 28-Oct-2015 No. of pages: 95 Single User License: US $2000 Browse more Reports on Neurology therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/neurology-therapeutics . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

2. Drug Addiction - Pipeline Review, H2 2015 This report provides comprehensive information on the therapeutic development for Drug Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Drug Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

3. Drug Addiction - Pipeline Review, H2 2015 Companies Discussed/Mentioned in this Research: Addex Therapeutics Ltd, Aphios Corporation, Astellas Pharma Inc., Curemark, LLC, EmberaNeuroTherapeutics, Inc., Immunovaccine, Inc., Kyorin Pharmaceutical Co., Ltd., Lightlake Therapeutics Inc., Omeros Corporation, RottapharmSpA, Saniona AB and Teva Pharmaceutical Industries Limited Drugs Profile Discussed in this Research: (oxazepam + metyrapone), 18-MC, ADX-71441, ADX-88178, ASP-2905, cannabidiol, CM-1212, CR-5542 Series, dronabinol, Drug for Dependence, EROA-101, ibudilast, JQ-1, LT-22, MC-100093, N-S2359, OMS-527, Small Molecule for Drug Addiction, Small Molecule to Activate Kappa Opioid Receptor for CNS, Small Molecules to Activate Delta Opioid Receptor for Immunology, CNS and Metabolic Disorders, Small Molecules to Block VMAT2 for Methamphetamine Addiction, Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction, Small Molecules to Inhibit DAT and SERT for CNS Disorders, Small Molecules to Inhibit Kappa Opioid Receptor for CNS, Small Molecules to Target 5HT2 for CNS and Metabolic Disorders, Synthetic Peptide to Target Kappa Opioid Receptors for Drug Addiction, TV-1380, Vaccine for Cocaine Addiction, Vaccine for Cocaine Addiction and Vaccine for Methamphetamine Addiction ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

4. Drug Addiction - Pipeline Review, H2 2015 Scope For Drug Addiction - Pipeline Review, H2 2015 • The report provides a snapshot of the global therapeutic landscape of Drug Addiction • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Drug Addiction and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Drug Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages • A detailed assessment of monotherapy and combination therapy pipeline projects • Coverage of the Drug Addiction pipeline on the basis of target, MoA, route of administration and molecule type ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

5. Drug Addiction - Pipeline Review, H2 2015 Reasons to Buy: • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Drug Addiction • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Drug Addiction pipeline depth and focus of Indication therapeutics • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

6. Drug Addiction - Pipeline Review, H2 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441